Literature DB >> 2318143

Differential effects of continuous and transient treatment with parathyroid hormone related peptide (PTHrp) on bone collagen synthesis.

E Canalis1, T L McCarthy, M Centrella.   

Abstract

Parathyroid hormone-related peptide (PTHrp), a polypeptide synthesized by tumors associated with hypercalcemia and known to cause bone resorption, was examined for its effects on bone formation in cultures of 21-day fetal rat calvariae. Continuous treatment with PTHrp for 24-72 h stimulated DNA synthesis, but inhibited [3H] proline incorporation into collagen by about 50%. In contrast, transient exposure to PTHrp at 0.1-1.0 nM for 24 h followed by removal of the factor for 48 h caused an increase in [3H]proline incorporation into collagen and noncollagen protein by 2- and 1.6-fold, respectively. The stimulatory effect was seen in the periosteum-free bone, and was decreased, but not prevented by hydroxyurea. PTHrp at 1-10 nM for 24 h increased medium insulin-like growth factor (IGF) I levels by 2.5-4.4-fold, and the effect was sustained 48 h after the removal of the agent. An IGF I neutralizing antibody prevented the stimulatory effect of PTHrp on bone collagen synthesis. PTH had the same stimulatory effects as those of PTHrp on bone collagen synthesis and IGF I concentrations, although slightly lower doses were needed to observe the enhancement of [3H]proline incorporation into collagen. It is concluded that continuous treatment with PTHrp inhibits, whereas transient treatment stimulates, collagen synthesis; the stimulatory effect appears mediated by an enhancement in the local production of IGF I.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2318143     DOI: 10.1210/endo-126-4-1806

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  8 in total

Review 1.  PTH and PTHrP effects on the skeleton.

Authors:  A C Karaplis; D Goltzman
Journal:  Rev Endocr Metab Disord       Date:  2000-11       Impact factor: 6.514

Review 2.  Parathyroid hormone-like peptide.

Authors:  Daniel J Drucker
Journal:  Endocr Pathol       Date:  1991-03       Impact factor: 3.943

3.  Expression of parathyroid hormone-related peptide (PthrP) and its receptor (PTH1R) during the histogenesis of cartilage and bone in the chicken mandibular process.

Authors:  Qiong Zhao; Philip R Brauer; Lei Xiao; Michael H McGuire; John A Yee
Journal:  J Anat       Date:  2002-08       Impact factor: 2.610

Review 4.  MANAGEMENT OF ENDOCRINE DISEASE: Novel anabolic treatments for osteoporosis.

Authors:  Ernesto Canalis
Journal:  Eur J Endocrinol       Date:  2017-11-07       Impact factor: 6.664

Review 5.  Hypercalcemia in malignancy.

Authors:  G J Strewler; R A Nissenson
Journal:  West J Med       Date:  1990-12

6.  Synthetic parathyroid hormone-like protein (1-74) is anabolic for bone in vivo.

Authors:  E C Weir; G Terwilliger; L Sartori; K L Insogna
Journal:  Calcif Tissue Int       Date:  1992-07       Impact factor: 4.333

7.  Disruption of insulin-like growth factor-I expression in type IIalphaI collagen-expressing cells reduces bone length and width in mice.

Authors:  Kristen E Govoni; Seong Keun Lee; Yoon-Sok Chung; Richard R Behringer; Jon E Wergedal; David J Baylink; Subburaman Mohan
Journal:  Physiol Genomics       Date:  2007-05-22       Impact factor: 3.107

8.  Intermittent PTHrP(1-34) exposure augments chondrogenesis and reduces hypertrophy of mesenchymal stromal cells.

Authors:  Jennifer Fischer; Antje Aulmann; Verena Dexheimer; Tobias Grossner; Wiltrud Richter
Journal:  Stem Cells Dev       Date:  2014-07-02       Impact factor: 3.272

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.